Piecemeal Versus En Bloc Resection of Large Rectal Adenomas
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Sep 10, 2014
Trial Information
Current as of June 08, 2025
Terminated
Keywords
ClinConnect Summary
In 20 to 35% of colonoscopies due to symptoms or for prevention polyps, so-called adenoma, are found. Currently, colonoscopy is the best way to detect bowel tumors and polyps, since these can be biopsied and removed in one working process. If the size of adenoma is larger than 2 cm, resections are usually done in a hospital setting. Foremost for flat adenoma, the resection by snares piece by piece, the so-called piecemeal polypectomy, or piecemeal endoscopic mucosal resection (EMR), is state of the art. Resection will usually follow a submucosal saline injection (saline assisted polypectomy...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with large non pedunculated colorectal adenomas designated for endoscopic resection up to 15 cm ab ano, length 2 cm to 5 cm, maximum hemicircumferential
- • age \> 18 years
- • signed Informed Consent
- Exclusion Criteria:
- • adenomas smaller or larger than described above
- • more than one large rectal adenoma
- • adenomas with known or suspected carcinoma, proven by previous biopsies
- • adenomas with known or suspected carcinoma that do not seem to be resectable by endoscopy, e.g. ulcers, suspected infiltration of submucosa after endoscopic or ultrasound diagnostics
- • patients with chronic inflammatory bowel diseases
- • severe general disease, including metastasising carcinomas
- • coagulation abnormalities or anticoagulant drug use which make resection therapy impossible
- • bad general state of health (American Society of Anesthesiologists Classification (ASA) IV or more)
- • pregnancy and lactation
- • recurrence or leftover dysplasia after extended endoscopic or surgical therapy (transanal endoscopic microsurgery (TEM))
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Berlin, , Germany
Hamburg, , Germany
Regensburg, , Germany
Berlin, , Germany
Hildesheim, , Germany
Portsmouth, , United Kingdom
Patients applied
Trial Officials
Thomas Rösch, Prof. Dr.
Study Chair
University Hospital Eppendorf, Hamburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials